Continuing Mailed FOBT Program Ups CRC Screening Adherence

This article originally appeared here.
Share this content:
Continuing Mailed FOBT Program Ups CRC Screening Adherence
Continuing Mailed FOBT Program Ups CRC Screening Adherence

TUESDAY, Oct. 27, 2015 (HealthDay News) -- Continuing a centralized mailed fecal occult blood test (FOBT) program is beneficial for improving adherence to colorectal cancer (CRC) screening, according to a study published online Oct. 21 in Cancer.

Beverly B. Green, M.D., M.P.H., from Group Health Permanente in Seattle, and colleagues examined the effect of continuing a centralized FOBT mailed program on screening adherence. A total of 2,208 patients aged 52 to 75 years in a substudy of the Systems of Support to Increase Colon Cancer Screening and Follow-up trial were randomized in year three to continued automated interventions, which included mailed information regarding CRC screening choices and mailed stool kit tests (Continued group), or to a group in which the intervention was stopped (Stopped group).

The researchers found that patients in the Continued group had significantly higher adherence to CRC screening in year three than those in the Stopped group (53.3 versus 37.3 percent; P < 0.001); this difference was entirely attributable to greater completion of FOBT. Patients in the Continued group completing FOBT in both years one and two had the highest rate of year three CRC screening (77.2 percent), followed by patients who had completed screening in only one of the years (44.6 percent). Low rates were reported for those not completing screening within the first two years (18.1 percent).

"Research is needed regarding how to engage patients not completing CRC testing after being mailed at least two rounds of FOBT tests," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »